ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1855

­Identification of Autoreactive Cytotoxic T Cells in ANCA-Associated Vasculitis

Laura van Dam1, Shady Younis2, Jae-Seung Moon3, Mengrui Zhang4, Shima Parfasar4, Audra Horomanski3, orr Sharpe3, Jolijn van Leeuwen5, Tobias Lanz4, Cees van Kooten6, Onno Teng7 and William Robinson8, 1Stanford, Palo Alto, CA, 2Stanford University, Stanford, CA, 3Department of Immunology and Rheumatology, Stanford University, Stanford, CA, 4Department of Immunology and Rheumatology, Stanford University, Stanford, 5Department of Nephrology, Leiden University Medical Center, Leiden, Netherlands, 6Department of Nephrology, Leiden University Medical Center, Leiden, 7Leiden University Medical Center, Leiderdorp, Netherlands, 8Division of Immunology and Rheumatology, Stanford University, and VA Palo Alto Health Care System, Stanford, CA

Meeting: ACR Convergence 2024

Keywords: ANCA associated vasculitis, autoantigens, genomics, immunology, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare and severe autoimmune disease, characterized by a pauci-immune necrotizing vasculitis leading to inflammation and damage of major organs. ANCAs targeting proteinase-3 (PR3) or myeloperoxidase (MPO), and ANCA-producing B cells play a central role in the pathogenesis of AAV. Autoreactive T cells and their features are less well-studied, but recent studies emphasize their importance in AAV. In this study we aimed to investigate autoreactive T cells and their cytotoxic responses in AAV.

Methods: Single cell RNA and TCR sequencing combined with CITE-seq staining was performed of isolated T cells from healthy controls (HC) (n=4), anti-MPO+ AAV (n=5) and anti-PR3+ AAV (n=4) patients. Secondly, PBMCs of these patients were stimulated in vitro with anti-CD3, Np/pp65, MPO or PR3 autoantigens in combination with anti-CD28 and IL-2 for 72h. After culturing, T cells were analyzed with flow cytometry for activation, proliferation and cytotoxic responses.

Results: We identified 15 clusters of CD4+ and CD8+ T cells based upon differential gene expression in AAV patients (n=9) and HCs (n=4) (Fig 1A-C). Anti-PR3+ AAV patients exhibited increased effector memory cells re-expressing CD45RA+ (EMRA) GZMB+ CD8+ T cells (20.8%) versus HC (6.7%) (p=0.03) and anti-MPO+ AAV patients (7.2%) (p=0.04) (Fig 1B,D). Both anti-MPO+ and anti-PR3+ AAV patients had large populations of clonally hyperexpanded T cells, which were found mostly in the GZMB+ but also in the GZMK+ CD8+ T cell subsets, which was not observed in ­­­HCs (Fig 1E-F). Expanded T cells in AAV patients had increased expression of cytotoxic and tissue homing genes, such as GZMB, NKG7, CST7, CCL5, PRF1, GPR56, CX3CR1 and TBX21 (Fig 2A). Gene ontology (GO) pathway analysis demonstrated that the significantly upregulated genes of expanded T cells in AAV were involved in cell activation and positive regulation of the immune response (Fig 2B). Specifically, CD8 EMRA GZMB+ T cells of AAV patients had significantly increased expression of highlighted cytotoxic and tissue homing genes as compared to HCs (Fig 2C). Secondly, flow cytometry confirmed the increased proportion of CD8 EMRA and GZMB+ CD8+ T cells in anti-PR3 AAV patients (Fig 3A-C), whereas anti-MPO+ AAV patients had increased levels of GZMB+IFNy+ CD8+ T cells as compared to HCs (Fig 3C). 24h of anti-CD3/anti-CD28 stimulation, used as a positive control in the culture assay, induced GZMB+IFNy+ responses in CD8+ T cells in all samples, which was most pronounced in HCs, and not observed after MPO or PR3 stimulation in AAV patients (Fig 3D). On the other hand, MPO specifically induced expansion and proliferation of GZMK+IFNy+ CD8+ T cells in anti-MPO+ AAV patients, in contrast to anti-PR3+ AAV patients and HCs (Fig 3E).

Conclusion: This study demonstrated that clonally expanded cytotoxic CD8+ T cells are present in both anti-MPO+ and anti-PR3+ AAV patients, and we identified a specific autoreactive GZMK+IFNy+ CD8+ T cell subpopulation in anti-MPO+ AAV patients. The identification and characterization of pathogenic autoreactive T cells in AAV could provide novel insights into next-generation therapeutic targets for this autoimmune disease.

Supporting image 1

Figure 1. Single cell RNA sequencing of T cells from AAV patients and HCs. A) UMAP plot of 15 annotated clusters of CD4+ and CD8+ T cells in AAV
patients (n=9) and HCs (n=4). (B) Proportions of different T cell clusters among the groups. C) Bubble heatmap of selected marker genes showing average expression levels and the percentage expression across the annotated clusters. D) UMAP plot of annotated T cells in HC, anti-MPO+ and
anti-PR3+ AAV patients. E) UMAP plots of T cells integrated with TCR clonality. The level of clonal expansions was based upon the frequency of a specific clonotype defined by its unique paired TCRαβ sequence. Each group was indicated by different colors as shown in the legend. (F) The
proportion of the different levels of clonally expanded T cells was shown in each annotated cluster of CD4+ and CD8+ T cells for HC, anti-MPO+ and anti-PR3+ AAV patients.

Supporting image 2

Figure 2. Differentially expressed genes in expanded T cells in AAV. A) Volcano plot of differential gene expression analysis of expanded T cell clones in AAV patients (large and bigger) compared to singles. Each point represents a gene, reflecting log2 fold change (x-axis) and statistical significance (y-axis). Points above the log2 fold change threshold (>0.5) and significance threshold (p < 0.05) are highlighted in red. B) Gene ontology
pathway analysis of significantly upregulated genes of expanded T cells in AAV. C) Heatmap of pseudo bulk average gene expression in each individual patient for selected genes in CD8 EMRA GZMB+ T cells.

Supporting image 3

Figure 3. PBMC stimulation assay. Baseline flow cytometry showed A) percentage of CD4+ and CD8+ of total T cells in anti-MPO+ (n=8), anti-PR3+ (n=7) AAV and HCs (n=6), B) percentage of CD8+ T cell memory and naive subsets and C) percentage of GZMB, GZMK and/or IFNy expressing CD8+ T cells. E)
The percentage of Ki-67+GZMB+IFNy+ and F) Ki-67+GZMK+IFNy+ expressing CD8+ T cells after 24h of stimulation. Data are represented as median ±IQR. Two-way ANOVA, p* < 0.05, **< 0.01, *** < 0.001 **** <0.0001.


Disclosures: L. van Dam: None; S. Younis: None; J. Moon: None; M. Zhang: None; S. Parfasar: None; A. Horomanski: BeiGene, 5, Chemocentryx, 2, Gilead, 5, Principia, 5; o. Sharpe: None; J. van Leeuwen: None; T. Lanz: None; C. van Kooten: None; O. Teng: CSL Vifor, 2, 5, Novartis, 2; W. Robinson: Atreca Inc, 2, 4, 8, Jansen, 5, Sanofi, 5.

To cite this abstract in AMA style:

van Dam L, Younis S, Moon J, Zhang M, Parfasar S, Horomanski A, Sharpe o, van Leeuwen J, Lanz T, van Kooten C, Teng O, Robinson W. ­Identification of Autoreactive Cytotoxic T Cells in ANCA-Associated Vasculitis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/identification-of-autoreactive-cytotoxic-t-cells-in-anca-associated-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-autoreactive-cytotoxic-t-cells-in-anca-associated-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology